Geovax Labs (GOVX)

May 28, 2026, 11:00 AM EDT - 6 weeks ago

GeoVax Labs Transcript: Investor update

2026-05-26T16:25:42.000Z - 6 weeks ago

GeoVax Labs discontinues development of COVID-19 vaccine candidate

2026-05-26T16:24:55.000Z - 6 weeks ago

Roth Capital ‘strongly’ agrees with GeoVax ending COVID-19 development

2026-05-26T14:06:13.000Z - 6 weeks ago

GeoVax Labs files to sell 7.64M shares of common stock for holders

May 26, 2026, 8:00 AM EDT - 6 weeks ago

GeoVax Labs Registration statement: Registration filing

2026-05-19T16:21:43.000Z - 7 weeks ago

3 Penny Stocks to Watch Now, 5/19/26

AIIO SBFM

May 18, 2026, 8:00 AM EDT - 7 weeks ago

GeoVax Labs Proxy statement: Proxy filing

May 14, 2026, 7:00 AM EDT - 2 months ago

GeoVax Labs Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

GeoVax Labs Earnings release: Q1 2026

May 8, 2026, 8:00 AM EDT - 2 months ago

GeoVax Labs Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

GeoVax Labs Proxy statement: Proxy filing

2026-04-17T15:35:10.000Z - 2 months ago

GeoVax Labs price target lowered to $10 from $14 at Roth Capital

Apr 16, 2026, 8:00 AM EDT - 3 months ago

GeoVax Labs Registration statement: Registration filing

Apr 16, 2026, 8:00 AM EDT - 3 months ago

GeoVax Labs Registration statement: Registration filing

Apr 16, 2026, 8:00 AM EDT - 3 months ago

GeoVax Labs Proxy statement: Proxy filing

2026-04-16T10:11:41.000Z - 3 months ago

GeoVax Labs files to sell 1.27M shares of common stock for holders

2026-04-16T10:10:12.000Z - 3 months ago

GeoVax Labs files to sell 865,804 shares of common stock for holders

Apr 15, 2026, 7:00 AM EDT - 3 months ago

GeoVax Labs Annual report: Q4 2025

Apr 15, 2026, 7:00 AM EDT - 3 months ago

GeoVax Labs Earnings release: Q4 2025

2026-02-19T13:49:42.000Z - 5 months ago

GeoVax Labs downgraded to Hold from Buy at D. Boral Capital

Jan 13, 2026, 5:30 PM EST - 6 months ago

GeoVax Labs Transcript: Biotech Showcase 2026

2026-01-10T00:50:28.000Z - 6 months ago

Geovax Labs Inc trading halted, news pending

2025-12-12T22:30:17.000Z - 7 months ago

GeoVax Labs files to sell 18.29M units

Dec 12, 2025, 7:00 AM EST - 7 months ago

GeoVax Labs Registration statement: Registration Filing

Nov 13, 2025, 4:30 PM EST - 8 months ago

GeoVax Labs Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

GeoVax Labs Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

GeoVax Labs Quarterly report: Q3 2025

2025-10-17T20:45:13.000Z - 9 months ago

GeoVax Labs files to sell 11.9M shares of common stock for holders

Oct 17, 2025, 8:00 AM EDT - 9 months ago

GeoVax Labs Registration statement: Registration Filing

Oct 14, 2025, 8:00 AM EDT - 9 months ago

GeoVax Labs Proxy statement: Proxy Filing

Oct 3, 2025, 8:00 AM EDT - 9 months ago

GeoVax Labs Proxy statement: Proxy Filing

Sep 25, 2025, 3:55 PM EDT - 10 months ago

GeoVax Labs Transcript: Emerging Growth Conference 2025

Sep 8, 2025, 7:00 AM EDT - 10 months ago

GeoVax Labs Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 3:40 PM EDT - 11 months ago

GeoVax Labs Transcript: Emerging Growth Conference 85

2025-08-07T18:45:57.000Z - 1 year ago

HHS mRNA vaccine decision bodes well for GeoVax Labs, says Roth Capital

Jul 28, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings Call Transcript: Q2 2025

Jul 28, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings release: Q2 2025

Jul 28, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Quarterly report: Q2 2025

2025-07-24T18:10:23.000Z - 1 year ago

Meet GeoVax Labs: Fly exclusive interview with CEO David Dodd

Jun 26, 2025, 8:00 AM EDT - 1 year ago

GeoVax Labs Registration statement: Registration Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

GeoVax Labs Registration statement: Registration Filing

May 1, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Quarterly report: Q1 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

GeoVax Labs Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

GeoVax Labs Proxy statement: Proxy Filing

Mar 27, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Earnings release: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

GeoVax Labs Annual report: Q4 2024

Feb 19, 2025, 2:55 PM EST - 1 year ago

GeoVax Labs Transcript: Emerging Growth Conference 79

Jan 16, 2025, 2:35 PM EST - 1 year ago

GeoVax Labs Transcript: Emerging Growth Conference 78

Dec 9, 2024, 9:00 AM EST - 1 year ago

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

Nov 26, 2024, 9:00 AM EST - 1 year ago

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

Nov 12, 2024, 4:30 PM EST - 1 year ago

GeoVax Labs Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

GeoVax Labs Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

GeoVax Labs Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 9:00 AM EST - 1 year ago

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

Oct 2, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

GeoVax Labs Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 6, 2024, 8:00 AM EDT - 1 year ago

GeoVax Labs Registration statement: Registration Filing

Sep 6, 2024, 8:00 AM EDT - 1 year ago

GeoVax Labs Registration statement: Registration Filing

Sep 3, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 8:59 PM EDT - 2 years ago

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Aug 20, 2024, 8:09 AM EDT - 2 years ago

GeoVax's stock slides 20% after company raises $8.5 million in stock sale

Aug 20, 2024, 7:45 AM EDT - 2 years ago

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Aug 20, 2024, 7:00 AM EDT - 2 years ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS IMRN

Aug 19, 2024, 7:30 AM EDT - 2 years ago

GeoVax's stock soars 54% to lead rally in companies developing mpox treatments

Aug 15, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Aug 15, 2024, 8:36 AM EDT - 2 years ago

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

EBS SIGA

Aug 8, 2024, 9:00 AM EDT - 2 years ago

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

Aug 6, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Earnings release: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Registration statement: Registration Filing

Aug 1, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Jul 31, 2024, 10:15 AM EDT - 2 years ago

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

Jul 22, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Jun 7, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Registration statement: Registration Filing

May 14, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

GeoVax Labs Earnings release: Q1 2024

Apr 15, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Apr 4, 2024, 12:30 PM EDT - 2 years ago

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Apr 3, 2024, 8:00 AM EDT - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Mar 28, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

Mar 18, 2024, 5:30 PM EDT - 2 years ago

GeoVax Labs Transcript: Roth MKM 36th Annual ROTH Conference

Mar 12, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Present at the 36th Annual Roth Conference

Mar 6, 2024, 9:00 AM EST - 2 years ago

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

Mar 1, 2024, 7:00 AM EST - 2 years ago

GeoVax Labs Registration statement: Registration Filing

Feb 29, 2024, 4:30 PM EST - 2 years ago

GeoVax Labs Earnings Call Transcript: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

GeoVax Labs Earnings release: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

GeoVax Labs Annual report: Q4 2023

Feb 29, 2024, 4:00 PM EST - 2 years ago

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Feb 22, 2024, 9:00 AM EST - 2 years ago

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

Feb 19, 2024, 9:00 AM EST - 2 years ago

GeoVax to Present at the 2024 BIO CEO & Investor Conference

Feb 13, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Multiple Patent Issuances and Allowances

Feb 6, 2024, 9:00 AM EST - 2 years ago

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Jan 29, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Jan 8, 2024, 5:30 PM EST - 2 years ago

GeoVax Labs Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 9:00 AM EST - 2 years ago

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

Jan 4, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

Jan 3, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Issuance of Malaria Vaccine Patent

Jan 2, 2024, 7:00 AM EST - 2 years ago

GeoVax Labs Registration statement: Registration Filing

Dec 27, 2023, 9:00 AM EST - 2 years ago

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

Dec 19, 2023, 9:00 AM EST - 2 years ago

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Nov 30, 2023, 4:30 PM EST - 2 years ago

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

Nov 29, 2023, 9:00 AM EST - 2 years ago

GeoVax to Participate in Upcoming December Investor Events

Nov 28, 2023, 9:00 AM EST - 2 years ago

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

Nov 27, 2023, 7:00 AM EST - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Nov 17, 2023, 7:00 AM EST - 2 years ago

GeoVax Labs Proxy statement: Proxy Filing

Nov 14, 2023, 9:00 AM EST - 2 years ago

Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

Nov 8, 2023, 4:30 PM EST - 2 years ago

GeoVax Labs Earnings Call Transcript: Q3 2023

Nov 8, 2023, 4:30 PM EST - 2 years ago

GeoVax Labs Quarterly report: Q3 2023

Nov 8, 2023, 4:30 PM EST - 2 years ago

GeoVax Labs Earnings release: Q3 2023

Nov 8, 2023, 4:00 PM EST - 2 years ago

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 30, 2023, 9:00 AM EDT - 2 years ago

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Oct 25, 2023, 9:00 AM EDT - 2 years ago

GeoVax to Participate in Upcoming November Investor and Industry Events

Oct 24, 2023, 9:00 AM EDT - 2 years ago

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

Oct 9, 2023, 9:00 AM EDT - 2 years ago

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Oct 5, 2023, 9:00 AM EDT - 3 years ago

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

Sep 27, 2023, 9:00 AM EDT - 3 years ago

GeoVax to Participate in Upcoming October Investor and Industry Events

Sep 20, 2023, 9:00 AM EDT - 3 years ago

GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference

Sep 19, 2023, 9:00 AM EDT - 3 years ago

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

Sep 12, 2023, 9:00 AM EDT - 3 years ago

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 11, 2023, 9:00 AM EDT - 3 years ago

GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

Aug 31, 2023, 9:00 AM EDT - 3 years ago

GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 29, 2023, 9:00 AM EDT - 3 years ago

GeoVax to Present at the Emerging Growth Conference on September 6, 2023

Aug 28, 2023, 9:00 AM EDT - 3 years ago

GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

Aug 10, 2023, 9:00 AM EDT - 3 years ago

GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia